Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial

We recently reported in the phase 3 PANAMO trial that selectively blocking complement 5a (C5a) with vilobelimab led to improved survival in critically ill COVID-19 patients. C5a is an important contributor to the innate immune system and can also activate the coagulation system. High C5a levels have...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Endry H. T., Vlaar, Alexander P. J., Bos, Lieuwe D. J., van Vught, Lonneke A., Boer, Anita M. Tuip-de, Dujardin, Romein W. G., Habel, Maria, Xu, Zhongli, Brouwer, Matthijs C., van de Beek, Diederik, de Bruin, Sanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789513/
https://www.ncbi.nlm.nih.gov/pubmed/36566174
http://dx.doi.org/10.1186/s12931-022-02278-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789513/
https://www.ncbi.nlm.nih.gov/pubmed/36566174
http://dx.doi.org/10.1186/s12931-022-02278-1

Ejemplares similares